LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

1.99 2.58

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.99

Max

2.01

Chiffres clés
By Trading Economics
Revenu	-3.8M -43M
BPA	-0.18
Employés	150
EBITDA	-3.9M -43M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+335.5% upside

Dividendes
By Dow Jones
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-117M 670M
Ouverture précédente	-0.59
Clôture précédente	1.99

Sentiment de l'Actualité

By Acuity

50%

151 / 345 Classement par Healthcare

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 mai 2026, 08:24 UTC

Principaux Mouvements du Marché

Acquisitions, Fusions, Rachats

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mai 2026, 21:22 UTC

Résultats

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mai 2026, 20:50 UTC

Market Talk

Résultats

Basic Materials Roundup: Market Talk

25 mai 2026, 16:20 UTC

Market Talk

Résultats

Basic Materials Roundup: Market Talk

25 mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mai 2026, 12:56 UTC

Market Talk

Résultats

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mai 2026, 12:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Delivery Hero's Assets Look Strategic -- Market Talk

25 mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mai 2026, 10:05 UTC

Résultats

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mai 2026, 10:04 UTC

Résultats

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mai 2026, 10:03 UTC

Résultats

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mai 2026, 10:02 UTC

Résultats

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mai 2026, 10:01 UTC

Résultats

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mai 2026, 10:00 UTC

Résultats

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q EPS MYR0.1883

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q Rev MYR17.1B

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q Net MYR1.1B

25 mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

335.5% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 335.5%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

151 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.